Side-Effect Profile of Brimonidine Tartrate in Children

Al-Shahwan, Sami; Al-Torbak, Abdullah; Turkmani, Shahira Al; Al-Omran, Mamdouh; Aljadaan, Ibrahim; Edward, Deepak P.

doi:10.1016/j.ophtha.2005.06.035

Cited by 83 publications

(36 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…11,12 Although these effects subsided after discontinuation of the drug, brimonidine should be used with caution in children. Figure 3 summarizes the effects of adrenergic agonists on pupil diameter, accommodation and anterior ocular vasculature.…”

Section: Discussionmentioning

confidence: 99%

Brimonidine and apraclonidine as vasoconstrictors in adjustable strabismus surgery

Dahlmann‐Noor¹,

Cosgrave

Lowe

et al. 2009

Journal of American Association for Pediatric Ophthalmology and

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Brimonidine and apraclonidine as vasoconstrictors in adjustable strabismus surgery

Dahlmann‐Noor¹,

Cosgrave

Lowe

et al. 2009

Journal of American Association for Pediatric Ophthalmology and

View full text Add to dashboard Cite

“…5 In that report, a number of children were being treated with apraclonidine in addition to brimonidine; hence, it is not clear what proportion of these adverse effects could be attributed to apraclonidine. No adverse events have been reported with a single drop of apraclonidine when used in the diagnosis of Horner syndrome.…”

Section: Discussionmentioning

confidence: 99%

Adverse effects of apraclonidine used in the diagnosis of Horner syndrome in infants

Watts

Satterfield

Lim

2007

Journal of American Association for Pediatric Ophthalmology and

View full text Add to dashboard Cite

“…[86][87][88][89][90] Brimonidine, an adrenergic agonist, must be avoided in neonates, infants, and young children, in consideration of central nervous system toxicity. [91][92][93][94] In PCG, prostaglandin analogus and prostamides are mainly used as adjunctive medication. [95][96][97][98] JOAG is more responsive to topical anti-glaucoma therapies, with prostaglandin analogs or beta-blockers usually prescribed as first drugs.…”

Section: Medical Therapymentioning

confidence: 99%

Pediatric glaucoma: current perspectives

Marchini¹,

Toscani²,

Chemello³

2014

PHMT

View full text Add to dashboard Cite

"Childhood glaucoma" is a heterogeneous group of severe pediatric conditions often associated with significant visual loss and characterized by elevated intraocular pressure (IOP) and optic-disk cupping. Successful IOP control is crucial but challenging and most often achieved surgically, with medical therapy playing a supportive role. There are many classifications of childhood glaucoma, but they can simply be divided into primary, in which a developmental abnormality of the anterior chamber angle only exists, and secondary, in which aqueous outflow is reduced due to independent mechanisms that secondarily impair the function of the filtration angle. The worldwide prevalence of childhood blindness ranges from 0.03% in high-income countries to 0.12% in undeveloped countries. The majority of cases do not have an identified genetic mutation and, where the mutation is known, the genes often account for only a small proportion of cases. Several pathogenetic mechanisms are known to contribute to the development of childhood glaucoma. Whatever the cause, it results in a reduced aqueous outflow at the level of the trabecular meshwork. Age of onset and magnitude of the elevated IOP largely determine the clinical manifestation the high variability of clinical manifestations. Glaucoma from any cause in a neonate and infant is characterized by the classic triad of epiphora, photophobia, and blepharospasm, and could be associated with eye enlargement (buphthalmos) and Haab striae. The eye examination, usually performed under general anesthesia, includes: tonometry, anterior-segment examination, gonioscopy, corneal diameter and axial length measurement, dilated fundoscopy with optic-nerve-head evaluation. Medical therapy, considering the high frequency of side effects, is generally used as temporizing IOP-lowering treatment before surgery or as adjuvant treatment postoperatively in case of partially successful procedures for refractory glaucomas. Surgery is the nodal point of the management of refractory childhood glaucoma, so it is crucial to opt for a forward-looking strategy to reach the target IOP and minimize the visual loss.

show abstract

Side-Effect Profile of Brimonidine Tartrate in Children

Cited by 83 publications

References 9 publications

Brimonidine and apraclonidine as vasoconstrictors in adjustable strabismus surgery

Brimonidine and apraclonidine as vasoconstrictors in adjustable strabismus surgery

Adverse effects of apraclonidine used in the diagnosis of Horner syndrome in infants

Pediatric glaucoma: current perspectives

Contact Info

Product

Resources

About